Cirmtuzumab, an inhibitory monoclonal antibody targeting ROR1, has already undergone a Phase I clinical trial in CLL patients with the conclusion that it is safe and well tolerated14. The gene discussed is ROR1; the disease is B-cell chronic lymphocytic leukemia.